Medical treatment of diabetic retinopathy

Eye

Volumn 17, Issue 5, 2003, Pages 550-562

  Donaldson, M ^a   Dodson, P M ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8' CHLORO 2',3' DIHYDROSPIRO[PYRROLIDINE 3,6'(5'H) PYRROLO[1,2,3 DE][1,4]BENZOXAZINE] 2,5,5' TRIONE; ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROPAMIDE; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EPALRESTAT; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; IRBESARTAN; LOSARTAN; PONALRESTAT; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SORBINIL; SORBITOL; TICLOPIDINE; TOLRESTAT; UNINDEXED DRUG; VASCULOTROPIN; ZENARESTAT; ZOPOLRESTAT;

BLOOD RHEOLOGY; BLOOD VESSEL PERMEABILITY; COUGHING; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LASER COAGULATION; NEUTROPENIA; PATHOGENESIS; RETINA NEOVASCULARIZATION; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0043171007     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700586     Document Type: Review

References (90)

1. Anonymous. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976; 81(4): 383-396.
2. Anonymous. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103(12): 1796-1806.
3. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes 1989; 38(4): 491-498.
4. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(Suppl 5): 757-765.
5. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 1990; 108(9): 1234-1244.
6. Stratton IM, Adler AI, Neil HA, Mathews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405-412.
7. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102(4): 647-661.
8. Adler AI et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321(7258): 412-419.
9. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 349(9068): 1787-1792.
10. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
11. Archer DB. Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations. Eye 1999; 13(Part 4): 497-523.
12. Van Heyningen R. Formation of polyols by the lens of the rat with sugar cataract. Nature 1959; 184: 194-195.
13. Crabbe MJ, Goode D. Aldose reductase: a window to the treatment of diabetic complications? Prog Retin Eye Res 1998; 17(3): 313-383.
14. van Gerven JM et al. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol 1994; 87(4): 355-365.
15. The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. Arch Ophthalmol 1990; 108(11): 1577-1583.
16. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44(8): 968-983.
17. Dodson PM, Kritzinger EE. Medical cardiovascular treatment trials: relevant to medical ophthalmology in 1997? Eye 1997; 11(Part 1): 3-11.
18. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991; 90(4): 450-459.
19. Gray A et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000; 320(7246): 1373-1378.
20. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ 2000; 320(7251): 1720-1723.
21. Gillow JT, Gibson JM, Dodson PM. Hypertension and diabetic retinopathy - what's the story? Br J Ophthalmol 1999; 83(9): 1083-1087.
22. Dodson PM, Gibson JM. Long-term follow-up of and underlying medical conditions in patients with diabetic exudative maculopathy. Eye 1991; 5(Part 6): 699-703.
23. Klein R et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149(11): 2427-2432.
24. Klein R et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105(10): 1801-1815.
25. Gaede P et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353(9153): 617-622.
26. Chaturvedi N et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351(9095): 28-31.
27. Barnett AH. The Heart Outcomes Protection Evaluation (HOPE) study: relevance to ophthalmological practice? Eye 2000; 14(Part 1): 1-2.
28. McInnes GT. Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonist? J Hypertens Suppl 2001; 19(Suppl 1): S61-S67.
29. Gilbert RE et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43(11): 1360-1367.
30. Unger T, Azizi M, Betz GG. Blocking the tissue renin-angiotensin system: the future cornerstone of therapy. J Hum Hypertens 2000; 14(Suppl 2): S23-S31.
31. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
32. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
33. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
34. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345: 910-913.
35. Dahlof B, Devereux RB, Kleldsen SE et al. Cardivascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
36. Chew EY et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114(9): 1079-1084.
37. Klein BE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98(8): 1261-1265.
38. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348(9034): 1079-1082.
39. Gordon B et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; 112(4): 385-391.
40. Poulsen J. Recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes 1953; 2: 7-12.
41. Wright AD et al. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. BMJ 1969; 2(653): 346-348.
42. Forrester JV, Olson J, Pascal M, Robertson M, Muckersie E. Growth factors and diabetic retinopathy. Diabetes Rev Int 1997; 6(1): 9-11.
43. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993; 48(1-2): 267-278.
44. McCombe M et al. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye 1991; 5(Part 5): 569-575.
45. Mallet B et al. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab 1992; 18(6): 438 444.
46. Shumak SL et al. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study. Clin Invest Med 1990; 13(5): 287-292.
47. Kirkegaard C et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenhagen) 1990; 122(6): 766-772.
48. Grant MB et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23(4): 504-509.
49. Kuijpers RW, Baarsma S, van Hagen PM. Treatment of cystoid macular edema with octreotide. N Engl J Med 1998; 338(9): 624-626.
50. Luettke BLG, Boehm BO, Lang GK. Influence of a Somatostatin analogue on the course of persisting proliferative diabetic retinopathy after laser treatment. Invest Ophthalmol Vis Sci 1998; 39(S674): abstract 3100.
51. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001; 108: 226-227.
52. Yeo TK et al. Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). Biochem Biophys Res Commun 1991; 179(3): 1568-1575.
53. Tolentino MJ et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103(11): 1820-1828.
54. Xia P et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98(9): 2018-2026.
55. Prechnical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22(2): 143-152.
56. Donnelly R. Protein kinase C: a novel therapeutic target in microvascular complications. Mod Diabetes Manage 2000; 1(1): 13-16.
57. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47(6): 859-866.
58. Kirk Ways D, Protein kinase C beta and chronic complications of diabetes. Diabetes Rev Int 1998; 7(4): 9-12.
59. Koya D et al. d-alpha-tocopherol treatment prevents glomerular dysfunctions in diabetic rats through inhibition of protein kinase C-diacylglycerol pathway. Biofactors 1998; 7(1-2): 69-76.
60. Ishii H et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272(5262): 728-731.
61. Aiello LP et al. Vascular endothehal growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46(9): 1473-1480.
62. Danis RP et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39(1): 171-179.
63. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
64. Bucala R, Model P, Cerami A. Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 1984; 81(1): 105-109.
65. Howard EW et al. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp Cell Res 1996; 228(1): 132-137.
66. Paget C et al. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radical Biol Med 1998; 25(1): 121-129.
67. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001; 85(6): 746-753.
68. Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991; 40(10): 1016-1019.
69. Soulis-Liparota T et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40(10): 1328-1334.
70. Bach LA et al. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol Dial Transplant 2000; 15(3): 347-354.
71. Hammes HP et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88(24): 11555-11558.
72. Roufail E et al. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia 1998; 41(12): 1419-1425.
73. Huijberts MS et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993; 92(3): 1407-1411.
74. Brown CD et al. Correction of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine. Diabetes 1993; 42(4): 590-593.
75. Panagiotopoulos S et al. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998; 136(1): 125-131.
76. Kihara M et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88(14): 6107-6111.
77. Miyauchi Y et al. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats. Eur J Endocrinol 1996; 134(4): 467-473.
78. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50(7): 1636-1642.
79. Vasan S et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382(6588): 275-278.
80. Wolffenbuttel BH et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95(8): 4630-4634.
81. Asif M et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000; 97(6): 2809-2813.
82. Nakamura S et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46(5): 895-899.
83. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48(1): 1-9.
84. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251(2): 87-101.
85. Verdejo C et al. Lipid peroxidation in proliferative vitreoretinopathies. Eye 1999; 13(Part 2): 183-188.
86. Chung TW, Yu JJ, Liu DZ. Reducing lipid peroxidation stress of erythrocyte membrane by alpha-tocopherol nicotinate plays an important role in improving blood rheological properties in type 2 diabetic patients with retinopathy. Diabetic Med 1998; 15(5): 380-385.
87. Kunisaki M et al. Prevention of diabetes-induced abnormal retinal blood flow by treatment with d-alpha-tocopherol. Biofactors 1998; 7(1-2): 55-67.
88. Granado F et al. Carotenoids, retinol and tocopherols in patients with insulin-dependent diabetes mellitus and their immediate relatives. Clin Sci (Lond) 1998; 94(2): 189-195.
89. Dodson PM. Oral agents for retinopathy: from graveyard to hope? Mod Diabetes Manage 2001; 2(3): 1 (leading article).
90. Ferris FL, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999; 341: 667-678.